FDA‑approved Flow Neuroscience headset for depression launches in US

The U.S. Food and Drug Administration has granted clearance to a brain‑stimulation device developed by Flow Neuroscience, marking the first time the technology has been approved for use in adults with major depressive disorder. Marketed as a non‑invasive, at‑home treatment, the device delivers transcranial direct current stimulation (tDCS) to targeted regions of the prefrontal cortex, a method shown in clinical studies to reduce depressive symptoms and potentially enable patients to taper or discontinue antidepressant medication.

Flow Neuroscience’s system, which includes a headset and a mobile app that guides users through daily 30‑minute sessions, is priced at $2,200 per unit. The approval follows a multicenter trial in which participants receiving the device alongside standard care reported statistically significant improvements in mood scores compared with a sham‑control group. While the cost places the product outside typical insurance coverage, the company plans to offer financing options and is seeking reimbursement pathways. If widely adopted, the device could expand the range of non‑pharmacologic options for depression, offering an alternative for individuals seeking to reduce reliance on medication.